Clinical trial
Safety of Everolimus in Combination Therapy, in Patients With…
NCT00426530 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00426530 |
|---|---|
| Title | Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer |
| Official title | A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | everolimus (RAD001) |
| Enrollment | 50 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Jan 24, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | Belgium, France, Italy, Poland, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: